<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: competitive", fill: "#8e4585"},
{source: "2: competitive", target: "2: environment", fill: "#8e4585"},
{source: "2: environment", target: "2: to a Company ", fill: "#8e4585"},
{source: "2: to a Company ", target: "2: cannot guarantee", fill: "#8e4585"},
{source: "2: cannot guarantee", target: "2: forwardlooking", fill: "#8e4585"},
{source: "2: competitive", target: "3: Important ", fill: "#ff6700"},
{source: "3: Important ", target: "3: differ materially from", fill: "#ff6700"},
{source: "3: differ materially from", target: "3: The Company ", fill: "#ff6700"},
{source: "3: The Company ", target: "3: depends on", fill: "#ff6700"},
{source: "3: depends on", target: "3: development manufacture", fill: "#ff6700"},
{source: "3: development manufacture", target: "3: future success", fill: "#ff6700"},
{source: "3: Important ", target: "4: future success", fill: "#00bfff"},
{source: "4: future success", target: "4: largely dependent upon", fill: "#00bfff"},
{source: "4: largely dependent upon", target: "4: manufacture", fill: "#00bfff"},
{source: "4: manufacture", target: "4: market commercially successful new products", fill: "#00bfff"},
{source: "4: future success", target: "5: Generally ", fill: "#ffa812"},
{source: "5: Generally ", target: "5: depends on", fill: "#ffa812"},
{source: "5: depends on", target: "5: effective", fill: "#ffa812"},
{source: "5: effective", target: "5: regulatory approvals", fill: "#ffa812"},
{source: "5: regulatory approvals", target: "5: manufacture", fill: "#ffa812"},
{source: "5: manufacture", target: "5: timely manner", fill: "#ffa812"},
{source: "5: Generally ", target: "8: development", fill: "#ff2800"},
{source: "8: development", target: "8: expenditures", fill: "#ff2800"},
{source: "8: expenditures", target: "8: negatively", fill: "#ff2800"},
{source: "8: development", target: "12: The Company ", fill: "#f1a7fe"},
{source: "12: The Company ", target: "12: government regulations", fill: "#f1a7fe"},
{source: "12: government regulations", target: "12: could prevent", fill: "#f1a7fe"},
{source: "12: could prevent", target: "12: from marketing", fill: "#f1a7fe"},
{source: "12: from marketing", target: "12: certain countries", fill: "#f1a7fe"},
{source: "12: The Company ", target: "14: Government ", fill: "#483c32"},
{source: "14: Government ", target: "14: controls over testing manufacturing", fill: "#483c32"},
{source: "14: controls over testing manufacturing", target: "14: safety efficacy labeling record", fill: "#483c32"},
{source: "14: safety efficacy labeling record", target: "14: pricing sale", fill: "#483c32"},
{source: "14: pricing sale", target: "14: distribution", fill: "#483c32"},
{source: "14: distribution", target: "14: pharmaceutical products", fill: "#483c32"},
{source: "14: Government ", target: "15: While the Company ", fill: "#fafad2"},
{source: "15: While the Company ", target: "15: compliance with", fill: "#fafad2"},
{source: "15: compliance with", target: "15: government regulations", fill: "#fafad2"},
{source: "15: government regulations", target: "15: aggregate such regulations substantially increase", fill: "#fafad2"},
{source: "15: aggregate such regulations substantially increase", target: "15: manufacturing", fill: "#fafad2"},
{source: "15: While the Company ", target: "16: governments", fill: "#fe4164"},
{source: "16: governments", target: "16: manufacturing", fill: "#fe4164"},
{source: "16: manufacturing", target: "16: operations", fill: "#fe4164"},
{source: "16: operations", target: "16: Oslo Copenhagen and Budapest ", fill: "#fe4164"},
{source: "16: Oslo Copenhagen and Budapest ", target: "16: manufactured", fill: "#fe4164"},
{source: "16: governments", target: "22: Company ", fill: "#ffa500"},
{source: "22: Company ", target: "22: significant", fill: "#ffa500"},
{source: "22: significant", target: "22: operations", fill: "#ffa500"},
{source: "22: Company ", target: "25: antibiotics used", fill: "#c9dc87"},
{source: "25: antibiotics used", target: "25: animals could", fill: "#c9dc87"},
{source: "25: animals could", target: "25: total sales", fill: "#c9dc87"},
{source: "25: antibiotics used", target: "26: potential transfer", fill: "#004225"},
{source: "26: potential transfer", target: "26: antibiotics", fill: "#004225"},
{source: "26: antibiotics", target: "26: discussions on", fill: "#004225"},
{source: "26: discussions on", target: "26: worldwide basis", fill: "#004225"},
{source: "26: worldwide basis", target: "26: government restrictions on", fill: "#004225"},
{source: "26: potential transfer", target: "32: of the EU ", fill: "#dda0dd"},
{source: "32: of the EU ", target: "32: importation", fill: "#dda0dd"},
{source: "32: importation", target: "32: meat products from", fill: "#dda0dd"},
{source: "32: meat products from", target: "32: additional countries such as", fill: "#dda0dd"},
{source: "32: additional countries such as", target: "32: antibiotic feed", fill: "#dda0dd"},
{source: "32: antibiotic feed", target: "32: additives sold by", fill: "#dda0dd"},
{source: "32: additives sold by", target: "32: Company in the US ", fill: "#dda0dd"},
{source: "32: Company in the US ", target: "32: discontinue", fill: "#dda0dd"},
{source: "32: discontinue", target: "32: antibiotic feed additives", fill: "#dda0dd"},
{source: "32: antibiotic feed additives", target: "32: sales could", fill: "#dda0dd"},
{source: "32: sales could", target: "32: financial condition cash", fill: "#dda0dd"},
{source: "32: financial condition cash", target: "32: operations", fill: "#dda0dd"},
{source: "32: of the EU ", target: "START_HERE", fill: "#dda0dd"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Company">Company</a></td>
      <td>A company, abbreviated as co., is a legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective. Company members share a common purpose and unite to achieve specific, declared goals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Contract_manufacturing_organization">Contract manufacturing organization</a></td>
      <td>A contract manufacturing organization (CMO), more recently referred to (and more commonly used now) as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organization in the pharma industry, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Future_(rapper)">Future (rapper)</a></td>
      <td>Nayvadius DeMun Wilburn (born November 20, 1983), better known by the stage name Future, is an American rapper and singer. Known for his mumble-influenced vocal range and prolific output, Future is considered a pioneer of the use of melodies and vocal effects in modern trap music.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Expense">Expense</a></td>
      <td>An expense is an item requiring an outflow of money, or any form of fortune in general, to another person or group as payment for an item, service, or other category of costs. For a tenant, rent is an expense.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_expenditure">Public expenditure</a></td>
      <td>Public expenditure is spending made by the government of a country on collective needs and wants, such as pension, provisions (which includes education, healthcare and housing), security, infrastructure, etc. Until the 19th century, public expenditure was limited as laissez faire philosophies believed that money left in private hands could bring better returns.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_countries_by_total_health_expenditure_per_capita">List of countries by total health expenditure per capita</a></td>
      <td>This article includes 2 lists of countries of the world and their total expenditure on health per capita. Total expenditure includes both public and private expenditures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vehicle_regulation">Vehicle regulation</a></td>
      <td>Vehicle regulations are requirements that automobiles must satisfy in order to be approved for sale or use in a particular country or region. They are usually mandated by legislation, and administered by a government body.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Australian_Government">Australian Government</a></td>
      <td>The Australian Government, also known as the Commonwealth Government, is the national government of Australia, a federal parliamentary constitutional monarchy. Like other Westminster-style systems of government, the Australian Government is made up of three branches: the executive (the prime minister, the ministers, and government departments), the legislative (the Parliament of Australia), and the judicial.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_agency">Government agency</a></td>
      <td>A government or state agency, sometimes an appointed commission, is a permanent or semi-permanent organization in the machinery of government that is responsible for the oversight and administration of specific functions, such as an administration. There is a notable variety of agency types.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Executive_(government)">Executive (government)</a></td>
      <td>The executive (short for executive branch or executive power) is the part of government that enforces law, and has responsibility for the governance of a state.\nIn political systems based on the principle of separation of powers, authority is distributed among several branches (executive, legislative, judicial)—an attempt to prevent the concentration of power in the hands of a single group of people.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Local_government">Local government</a></td>
      <td>Local government is a generic term for the lowest tiers of public administration within a particular sovereign state. This particular usage of the word government refers specifically to a level of administration that is both geographically-localised and has limited powers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Military_government">Military government</a></td>
      <td>A military government is generally any government that is administered by military forces, whether or not this government is legal under the laws of the jurisdiction at issue, and whether this government is formed by natives or by an occupying power. It is usually carried out by military workers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Borne_government">Borne government</a></td>
      <td>The Borne government is the forty-third and current government of the French Fifth Republic, formed on 16 May 2022 and headed by Élisabeth Borne as Prime Minister under the presidency of Emmanuel Macron.\n\n\n== Context ==\n\n\n=== Formation ===\nOn 16 May 2022, Jean Castex tendered the resignation of his government to the President of the Republic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_of_Canada">Government of Canada</a></td>
      <td>The government of Canada (French: gouvernement du Canada) is the body responsible for the federal administration of Canada. A constitutional monarchy, the Crown is the corporation sole, assuming distinct roles: the executive, as the Crown-in-Council; the legislature, as the Crown-in-Parliament; and the courts, as the Crown-on-the-Bench.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Exponential_distribution">Exponential distribution</a></td>
      <td>In probability theory and statistics, the exponential distribution is the probability distribution of the time between events in a Poisson point process, i.e., a process in which events occur continuously and independently at a constant average rate. It is a particular case of the gamma distribution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Binomial_distribution">Binomial distribution</a></td>
      <td>In probability theory and statistics, the binomial distribution with parameters n and p is the discrete probability distribution of the number of successes in a sequence of n independent experiments, each asking a yes–no question, and each with its own Boolean-valued outcome: success (with probability p) or failure (with probability q = 1 − p). A single success/failure experiment is also called a Bernoulli trial or Bernoulli experiment, and a sequence of outcomes is called a Bernoulli process; for a single trial, i.e., n = 1, the binomial distribution is a Bernoulli distribution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Beta_distribution">Beta distribution</a></td>
      <td>In probability theory and statistics, the beta distribution is a family of continuous probability distributions defined on the interval [0, 1] parameterized by two positive shape parameters, denoted by alpha (α) and beta (β), that appear as exponents of the random variable and control the shape of the distribution. The generalization to multiple variables is called a Dirichlet distribution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pareto_distribution">Pareto distribution</a></td>
      <td>The Pareto distribution, named after the Italian civil engineer, economist, and sociologist Vilfredo Pareto, (Italian: [paˈreːto] US:  pə-RAY-toh), is a power-law probability distribution that is used in description of social, quality control, scientific, geophysical, actuarial, and many other types of observable phenomena. Originally applied to describing the distribution of wealth in a society, fitting the trend that a large portion of wealth is held by a small fraction of the population.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Antibiotic_use_in_livestock">Antibiotic use in livestock</a></td>
      <td>Antibiotic use in livestock is the use of antibiotics for any purpose in the husbandry of livestock, which includes treatment when ill (therapeutic), treatment of a group of animals when at least one is diagnosed with clinical infection (metaphylaxis), and preventative treatment (prophylaxis). Antibiotics are an important tool to treat animal as well as human disease, safeguard animal health and welfare, and support food safety.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Beta-lactam_antibiotics">Beta-lactam antibiotics</a></td>
      <td>β-lactam antibiotics (beta-lactam antibiotics) are antibiotics that contain a beta-lactam ring in their chemical \nstructure. This includes penicillin derivatives (penams), cephalosporins and cephamycins (cephems), monobactams, carbapenems and carbacephems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Production_of_antibiotics">Production of antibiotics</a></td>
      <td>Production of antibiotics is a naturally occurring event, that thanks to advances in science can now be replicated and improved upon in laboratory settings. Due to the discovery of penicillin by Alexander Flemming, and the efforts of Florey and Chain in 1938, large-scale, pharmaceutical production of antibiotics has been made possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Journal_of_Antibiotics">The Journal of Antibiotics</a></td>
      <td>The Journal of Antibiotics is a peer-reviewed medical journal published by the Nature Publishing Group for the Japan Antibiotics Research Association.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Glycopeptide_antibiotic">Glycopeptide antibiotic</a></td>
      <td>Glycopeptide antibiotics are a class of drugs of microbial origin that are composed of glycosylated cyclic or polycyclic nonribosomal peptides.  Significant glycopeptide antibiotics include the anti-infective antibiotics vancomycin, teicoplanin, telavancin, ramoplanin and decaplanin, corbomycin, complestatin and the antitumor antibiotic bleomycin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Antibiotic_misuse">Antibiotic misuse</a></td>
      <td>Antibiotic misuse, sometimes called antibiotic abuse or antibiotic overuse, refers to the misuse or overuse of antibiotics, with potentially serious effects on health. It is a contributing factor to the development of antibiotic resistance, including the creation of multidrug-resistant bacteria, informally called "super bugs": relatively harmless bacteria (such as Staphylococcus, Enterococcus and Acinetobacter) can develop resistance to multiple antibiotics and cause life-threatening infections.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ALPHARMA INC      Item 1A RISK FACTORS               The  Companyapstas  reports  filed  from time to time pursuant to the     <font color="blue">Securities Exchange Act </font>of 1934 include certain forward-looking statements</td>
    </tr>
    <tr>
      <td>Like any company subject to a <font color="blue">competitive</font> and changing business <font color="blue">environment</font>,     <font color="blue">the Company </font><font color="blue">cannot guarantee</font> the results predicted in any of the Companyapstas     forward-looking  statements</td>
    </tr>
    <tr>
      <td><font color="blue">Important </font>factors that could cause actual     results to <font color="blue">differ materially from</font> those in the forward-looking statements     include the following:          <font color="blue">The Company </font><font color="blue">depends on</font> the <font color="blue">development</font>, <font color="blue">manufacture</font> and marketing of new     products for its <font color="blue">future success</font></td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">future success</font> is <font color="blue">largely dependent upon</font> its ability to     develop,  <font color="blue">manufacture</font> and <font color="blue">market commercially successful <font color="blue">new products</font></font></td>
    </tr>
    <tr>
      <td>Generally, the successful commercial marketing of the Companyapstas products     <font color="blue">depends on</font> completing the following steps in a time frame to allow the     Company to be among the first to market a particular product:         * developing and testing the product;         * proving that the product is safe and <font color="blue">effective</font>; and         * filing for and receiving <font color="blue">regulatory approvals</font> to <font color="blue">manufacture</font> and sell         the product in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Delays in the <font color="blue">development</font>, <font color="blue">manufacture</font> or marketing of <font color="blue">new products</font>     will impact the Companyapstas expenses and revenues</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>cannot be sure     that any <font color="blue">product presently going through</font> the process set forth above, or     which may be <font color="blue">chosen by</font> <font color="blue">the Company </font>to enter this process in the future, will     result in the timely and <font color="blue">profitable commercial launch</font> of a new product</td>
    </tr>
    <tr>
      <td>Research and <font color="blue">development</font> <font color="blue">expenditures</font> will <font color="blue">negatively</font> impact the Companyapstas     earnings in the short term, and there is no guarantee of success</td>
    </tr>
    <tr>
      <td>The Company, in its continuing <font color="blue">businesses</font>, expended <font color="blue">approximately</font> dlra26dtta9     million and dlra25dtta4 million on research and <font color="blue">development</font> efforts in 2005 and     2004,  <font color="blue">respectively</font>,  and  expects  to  increase these <font color="blue">expenditures</font> to     <font color="blue">approximately</font>  dlra50 million in 2006, <font color="blue">principally</font> for the <font color="blue">development</font> of     <font color="blue"><font color="blue">additional</font> pain products</font></td>
    </tr>
    <tr>
      <td>Such research and <font color="blue">development</font> <font color="blue">expenditures</font> will     have an <font color="blue">adverse impact on</font> the Companyapstas earnings in the short term</td>
    </tr>
    <tr>
      <td>Further,     <font color="blue">the Company </font>cannot be sure that its research and <font color="blue">development</font> <font color="blue">expenditures</font>     will,  in  the long term, result in the <font color="blue">commercialization</font> of products,     including a next-generation pain product, which prove to be <font color="blue">economically</font>     successful</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is subject to <font color="blue"><font color="blue"><font color="blue">government</font> regulation</font>s</font> and actions that increase     the Companyapstas costs and <font color="blue">could prevent</font> it <font color="blue">from marketing</font> and selling some of     its products in <font color="blue">certain countries</font></td>
    </tr>
    <tr>
      <td>The research, <font color="blue">development</font>, <font color="blue">manufacturing</font> and marketing of the Companyapstas     products  are  subject  to extensive <font color="blue"><font color="blue">government</font> regulation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government     </font>regulation includes inspection of and controls over testing, <font color="blue">manufacturing</font>,     safety, efficacy, labeling, record keeping, pricing, sale and <font color="blue">distribution</font>     of <font color="blue">pharmaceutical products</font></td>
    </tr>
    <tr>
      <td><font color="blue">While <font color="blue">the Company </font></font>does not keep records that     segregate the cost of <font color="blue">compliance with</font> these <font color="blue"><font color="blue"><font color="blue">government</font> regulation</font>s</font>, in the     <font color="blue">aggregate such regulations substantially increase</font> the cost of <font color="blue">manufacturing</font>,     developing and selling the Companyapstas products</td>
    </tr>
    <tr>
      <td>The  US  and  other  <font color="blue"><font color="blue">government</font>s</font> regularly review <font color="blue">manufacturing</font>     <font color="blue">operations</font>, including APIapstas plants in Oslo, Copenhagen and Budapest where     products for the US market are, or are intended to be, <font color="blue">manufacture</font>d</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>reviews  can result in <font color="blue">regulatory concerns</font> requiring a <font color="blue">response by</font> the     Company</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">adequately</font> address these concerns could have a material     adverse effect on the Company, including product approval delays, reduced     production  and  production  <font color="blue">interruptions</font>,  among  other  things</td>
    </tr>
    <tr>
      <td>The     significance of the effect of any such failures <font color="blue">depends on</font> the severity of     the remedy <font color="blue">chosen by</font> the <font color="blue"><font color="blue">government</font> agency</font></td>
    </tr>
    <tr>
      <td>Non-<font color="blue">compliance with</font> applicable     <font color="blue">requirements</font> can result in fines, recall or seizure of products, suspension     of production or <font color="blue">distribution</font> and <font color="blue">debarment</font> of <font color="blue">individuals from providing</font>     services to <font color="blue">drug companies</font> in any <font color="blue">capacity</font> or <font color="blue">debarment</font> of <font color="blue">the Company </font>from     obtaining <font color="blue">new drug approvals</font>, resulting in <font color="blue">current charges</font> to income and the     potential for <font color="blue">future loss</font> of income and increased operating expenses</td>
    </tr>
    <tr>
      <td>In     recent years, besides stepped <font color="blue">up enforcement</font> of cGMP <font color="blue">requirements</font>, the     federal  <font color="blue">government</font>  has utilized equitable disgorgement as a means of     enforcing  <font color="blue">compliance with</font> the FDAapstas <font color="blue">cGMP regulations</font></td>
    </tr>
    <tr>
      <td>There can be no     assurance that the FDA would not seek to impose similar sanctions on the     <font color="blue">Company  </font>and  any such sanction could have a <font color="blue">significant</font> effect on the     Companyapstas business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, continuing studies of the proper utilization, safety and     efficacy of <font color="blue">pharmaceuticals</font> and other <font color="blue">health care products</font> are <font color="blue">continually</font>     being <font color="blue">conducted by</font> the industry, <font color="blue">government</font> agencies (including studies     required to be performed from time to time by the <font color="blue">pharmaceutical company</font>     marketing a <font color="blue">particular drug</font>) and others</td>
    </tr>
    <tr>
      <td>These studies, which increasingly     employ  more  <font color="blue">sophisticated</font>  methods  and <font color="blue">techniques</font>, can question the     <font color="blue">utilization safety</font> and efficacy of <font color="blue">previously marketed products</font> and in some     cases have resulted, and may in the future result, in the <font color="blue">discontinuance</font> of     their marketing and, in <font color="blue">certain countries</font>, give rise to claims for damages     from person who believe they have <font color="blue">been injured as</font> a result of their use</td>
    </tr>
    <tr>
      <td>An expansion of the ban of the use of <font color="blue"><font color="blue">antibiotics</font> used</font> in food-producing     <font color="blue">animals could</font> result in a decrease in the Companyapstas <font color="blue">total sales</font></td>
    </tr>
    <tr>
      <td>The issue of the <font color="blue">potential transfer</font> of increased bacterial resistance     to certain <font color="blue"><font color="blue">antibiotics</font> used</font> in certain food-producing animals to human     pathogens is the subject of <font color="blue">discussions on</font> a <font color="blue">worldwide basis</font> and, in certain     instances, has led to <font color="blue">government</font> restrictions on the use of <font color="blue">antibiotics</font> in     these food-producing animals</td>
    </tr>
    <tr>
      <td>While most of the <font color="blue">government</font> activity in this     area has <font color="blue">involved products</font> other than those that <font color="blue">the Company </font>offers for     sale, the <font color="blue">European Union </font>and one non-EU country banned the use of <font color="blue">bacitracin</font>     zinc, a feed antibiotic growth promoter <font color="blue">manufacture</font>d by <font color="blue">the Company </font>and     others that has been used in livestock feeds for over 40 years</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>    has not sold this product in these <font color="blue">countries since</font> the ban took effect</td>
    </tr>
    <tr>
      <td>The     EU ban is <font color="blue">based upon</font> the  &amp;quote <font color="blue">Precautionary Principle </font>&amp;quote , which states that a     <font color="blue">product may</font> be <font color="blue">withdrawn from</font> the market <font color="blue">based upon</font> a finding of a potential     threat of serious or <font color="blue">irreversible damage even</font> if such finding is not support     <font color="blue">ed by scientific certainty</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although the EU </font>action <font color="blue">negatively</font> impacted the     Companyapstas business, it was not material to the Companyapstas <font color="blue">financial position</font>     or its results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot predict whether</font> the present <font color="blue">bacitracin</font> zinc ban in     the EU will be expanded</td>
    </tr>
    <tr>
      <td>If any one of the following occur: (i) the EU or     countries within the EU act to prevent the <font color="blue">importation</font> of <font color="blue">meat products from</font>     countries that allow the use of <font color="blue">bacitracin</font>-based products, (ii) there is an     expansion of the zinc <font color="blue">bacitracin</font> ban to <font color="blue">additional</font> countries, such as the     US, where <font color="blue">the Company </font>has material sales of <font color="blue">bacitracin</font>-based products,     (iii)  a  similar  ban is instituted relating to other <font color="blue">antibiotic feed</font>     <font color="blue"><font color="blue">additives</font> sold by</font> <font color="blue">the Company </font>in the US or in one or more other countries     where <font color="blue">the Company </font>has material sales, or (iv) there is an increase in public     pressure to <font color="blue">discontinue</font> the use of <font color="blue">antibiotic feed</font> <font color="blue">additives</font>, the resultant     loss of <font color="blue">sales could</font> be material to the Companyapstas financial condition, cash     flows and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot predict whether</font> this     <font color="blue">antibiotic resistance</font> concern will result in <font color="blue">expanded regulations</font> or public     pressure adversely affecti ng other antibiotic-based animal health products     <font color="blue">previously sold by</font> <font color="blue">the Company </font>in the EU or in other countries in which     those products are <font color="blue">presently sold</font></td>
    </tr>
    <tr>
      <td><font color="blue">Discussions </font>of the <font color="blue">antibiotic resistance</font> issue continue actively in the     US Various sources have published reports <font color="blue">concerning possible adverse</font>     <font color="blue">human effects from</font> the use of <font color="blue">antibiotics</font> in <font color="blue">food animals</font></td>
    </tr>
    <tr>
      <td>Some of these     reports have asserted that major animal producers, some of whom are the     Companyapstas customers or the end-users of its products, are reducing the use     of  <font color="blue">antibiotics</font></td>
    </tr>
    <tr>
      <td>In July 2005, the FDA announced a <font color="blue">restriction on</font> the     <font color="blue">distribution</font> and use of a <font color="blue">medicated feed additive due</font> to concerns regarding     <font color="blue">antibiotic resistance</font> in humans</td>
    </tr>
    <tr>
      <td><font color="blue">While <font color="blue">the Company </font></font>does not market this drug     this <font color="blue">ruling would</font> be <font color="blue">significant</font> if its <font color="blue">conclusions</font> were expanded to the     medicated  feed  <font color="blue">additives</font>  sold  by the Company</td>
    </tr>
    <tr>
      <td>It is uncertain what     <font color="blue">additional</font>  actions, if any, the FDA may take for <font color="blue">approved animal drug</font>     products</td>
    </tr>
    <tr>
      <td>However, the FDA has proposed a <font color="blue">rating system</font> to be used to     compare the <font color="blue">risks associated with</font> the use of <font color="blue">specific antibiotic products</font> in     food producing animals, i ncluding those sold by the Company</td>
    </tr>
    <tr>
      <td>While the     Company does not believe that the <font color="blue">presently proposed risk assessment system</font>     would be <font color="blue">materially adverse</font> to its business, it is subject to change prior     to adoption or to <font color="blue">later amendment</font></td>
    </tr>
    <tr>
      <td>The sales of the Companyapstas Animal Health     segment  are  <font color="blue">principally</font>  antibiotic-based products for use with food     producing animals; therefore the <font color="blue">future loss</font> of <font color="blue">major markets</font>, including the     US, or negative publicity regarding this use of antibiotic based products,     could have a negative impact on the Companyapstas sales and income</td>
    </tr>
    <tr>
      <td><font color="blue">Potential  </font>adverse  effects  on  <font color="blue">human health linked</font> to the raising or     <font color="blue">consumption</font> of food producing <font color="blue">animals using</font> the Companyapstas <font color="blue">products could</font>     result in a decrease in the Companyapstas sales</td>
    </tr>
    <tr>
      <td>Should the <font color="blue">government</font> find, or the public perceive a risk to human     health from <font color="blue">consumption</font> of food producing animals (such as Avian flu) which     utilize the Companyapstas products or as a by-product to the raising of such</td>
    </tr>
  </tbody>
</table>